cafepharma

Thurs news: Lilly oral weight loss drug underdelivers. Merck had no competition for Verona. FDA announces program to boost US drug manufacturing. AZ’s lung cancer strategy. FTC challenges Edwards’ acquisition. —http://bit.ly/w28kSd

Wed news: Novo warns of job cuts. Alcon acquiring STAAR Surgical. Bayer expects more layoffs. RFK Jr. pulls federal vaccine funding. Pfizer CEO says US biotech needs federal support to match China. —http://bit.ly/w28kSd

Tue news: Strong quarterly results for Pfizer. July layoffs skyrocket 487% YOY. Trump says pharma tariffs may eventually be 250%. Corcym aortic valve robotically implanted. Vertex drops aspiring Journavx follower. —http://bit.ly/w28kSd

Mon news: Moderna’s Bancel on R&D partnerships. FDA leaks. Genentech five year data for wet AMD. BioNTech reaffirms 2025 guidance. Incyte’s new CEO. —http://bit.ly/w28kSd

Fri news: Regeneron earnings. Moderna wins patent battle against Pfizer/BioNTech. Medicare and Medicaid coverage may be coming for weight loss drugs. Moderna beats Street estimates. Merck to lay off 6000. —http://bit.ly/w28kSd

Thurs news: Moderna slashing 10% of workforce. Lilly’s Mounjaro shows cardio benefits. Earnings from Biogen, Sanofi, BMS. AbbVie looking to buy Gilgamesh Pharma. FDA direction in question after Prasad’s departure —http://bit.ly/w28kSd

Wed news: Takeda Vyvanse declines hit earnings. Novo slides further. Biogen/Eisai Alzheimer’s drug slows progression for 4 years in test. GSK shrugs off tariff threat. JNJ tests DTC CAR-T ads —http://bit.ly/w28kSd

Tue news: Novo names new CEO while cutting outlook. Merck cost-cutting. Lilly blood cancer med beats AbbVie’s. Bausch Health buys Direct. FDA takes U-turn on Sarepta’s Elevidys —http://bit.ly/w28kSd

Mon news: Novo expecting Wegovy growth after copycat ban. Roche Alzheimer’s therapy. GSK’s drugmaking alliance with a Chinese biotech. Could bispecifics unseat Keytruda? FDA delays decision on Bayer menopause drug. —http://bit.ly/w28kSd

Fri news: Sun Pharma, Taro agree on price fixing settlement. EMA reverses view on Lilly drug. Boehringer shows strong H1 growth. Pharma’s US manufacturing spending spree. Roche considers DTC sales. —http://bit.ly/w28kSd

Thurs news: AZ autoimmune drug succeeds in trial. Roche income soars. Novartis in $1B partnership with Matchpoint. How BMS uses AI to validate drugs. FDA extends review period for GSK’s Blenrep. —http://bit.ly/w28kSd

Wed news: FDA pilots commissioner voucher program. Dr Reddy’s to launch generic obesity drug. Pacira partners with JNJ to expand Zilretta. Genentech HQ layoffs. AbbVie wins $56M in Botox patent case. —http://bit.ly/w28kSd

Tue news: Sanofi buying UK biotech. Replimmune plummets on melanoma rejection. Novartis Zolgensma sales fall. Quest Diagnostics Q2 beat. Sarepta stops Elevidys shipments. —http://bit.ly/w28kSd

Mon news: Lack of US data affecting Roche’s earlier-stage lymphoma push. Heartflow IPO. Alkermes phase 2 narcolepsy win. Major patents losses this year for JNJ, Amgen, Regeneron. Sarepta tells FDA it won’t halt shipments. —http://bit.ly/w28kSd

Fri news: Survey show neurologists can’t recall drug names. BMS’ Reblozyl misses primary endpoint. Moderna cancels Japan plant plans. Third Sarepta gene therapy patient death. Biotech startup funding dried up in Q2. —http://bit.ly/w28kSd

Thurs news: BMS and Pfizer to offer Eliquis DTC. GSK prefilled shingles vaccine approved. CDER employees leaving FDA in droves. Abbott Labs has rare guidance miss. 500 Sarepta layoffs. —http://bit.ly/w28kSd

Wed news: JNJ earnings. Zimmer bets on robotic surgery. DOGE and biotech IPO filings. AZ amyloidosis trial. CMS deal with sickle cell drugmakers. —http://bit.ly/w28kSd

Tue news: China biotechs reshaping US biopharma. GSK eyes Blenrep’s US return. Quest to offer Alzheimer’s test. Kenvue CEO departure. Wojcicki wins back 23andMe. —http://bit.ly/w28kSd

Mon news: Takeda narcolepsy clinical wins. GSK seeks to expand RSV vaccine use. Novartis bets big on creativity. AZ preps to file hypertension drug. Makary lauds user fees. —http://bit.ly/w28kSd

Fri news: Karyopharm layoffs. CRL reveals. Biogen/Stoke Dravet syndrome drug. Walgreens PE buyout. Moderna COVID vax approved for high risk kids. —http://bit.ly/w28kSd

Thurs news: AbbVie buys $700M trispecific. Pfizer asks to overturn Moderna’s UK COVID vaccine patent win. Trump’s new pharma tariff threat. Medtech M&A. Biopharma layoffs up YOY. —http://bit.ly/w28kSd

Wed news: Merck buying Verona. Pfizer restructuring. FDA clears new safer dosing for Lilly Alzheimer drug. Novo files for high dose Wegovy in EU. Trump says pharma tariffs coming. —http://bit.ly/w28kSd

Tue news: ALS community petitions FDA about NurOwn. Novo and Lilly vie for India obesity drug market share. Samsung buys Xealth in digital health play. Novartis malaria approval. Wegovy takes top tv ad spend spot. —http://bit.ly/w28kSd

Mon news: Baxter taps new CEO. Funding heats up PFA market. Roche’s Chugai breaks into aging. NIH makes taxpayer-funded studies public. GLP-1 insurance roadblocks. —http://bit.ly/w28kSd

Thurs news: Summit in talks with AZ about Keytruda rival. Intuitive Surgical’s da Vinci 5 wins CE Mark. Novartis trial fail. RFK Jr, and the wearables market. Bluebird Bio going private and what is signals. —http://bit.ly/w28kSd

Wed news: Regeneron multiple myeloma approval. Gilead eyes HIV market domination. Organon endometriosis trial fail. US open to creative pharma trade solutions with EU. Trump tax bill and Medicaid spending. —http://bit.ly/w28kSd

Tue news: AZ CEO may move company listing to US. How Novo misread the US weight loss. Biogen phase III trial. Beckley psychedelic nose spray for depression. Brainlab’s delayed IPO. —http://bit.ly/w28kSd

Mon news: AbbVie buys Capstan for CAR-T. Sage lays off entire staff. BMS NJ layoffs. FDA takes major step to ease access to CAR-T therapy. Moderna’s new flu vax data. —http://bit.ly/w28kSd

Fri news: ACIP skips COVID and mRESVIA votes. VC legal dispute threatens biotech startups. MS market to reach $25.9B by 2034. Novo Nordisk Foundation gives $75M for R&D. Clinical hold on Gilead HIV studies. —http://bit.ly/w28kSd

Thurs news: Altimmune sinks on mixed phase 2 MASH results. Incyte CEO change. Lilly launching Mounjaro pen in India. RFK Jr’s ACIP recommends RSV shot for infants. Medtronic capsule delivery recall. —http://bit.ly/w28kSd